Spectranetics acquires balloon catheter company

Spectranetics Corp. and AngioScore penned a $230 million deal to serve the peripheral and coronary markets by making AngioScore a wholly owned subsidiary of Spectranetics.   

Spectranetics reported that it will pay $115 million in cash and $115 million in stock to complete the transaction, which is expected be final by the end of June.

AngioScore, of Freemont, Calif., develops, makes and markets specialty balloon catheters to be used in the treatment of coronary and peripheral artery diseases. Colorado Springs, Colo.-based Spectranetics offers minimally invasive laser technologies for vascular treatments, ablation catheters and cardiac lead management devices.